Results 201 to 210 of about 101,286 (277)

A Rare Case of Immune‐related Adverse Events Localized to the Small Intestine

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Enterocolitis is a common gastrointestinal manifestation of immune‐related adverse events (irAEs); however, only a few studies have reported on irAE enteritis with localized active inflammation in the small intestine. Here, we report the case of a 74‐year‐old man who developed diarrhea, abdominal pain, and oral intake difficulty and was ...
Ryo Morikawa, Ryosuke Kanaya, Hiromichi Shimizu, Masayoshi Fukuda, Yasuhiro Nemoto, Toshimitsu Fujii, Towako Taguchi, Kurara Yamamoto, Kazuo Ohtsuka, Ryuichi Okamoto   +9 more
wiley   +1 more source

The cost-effectiveness analysis of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair deficient advanced colorectal cancer. [PDF]

Sci Rep
Yang P, Pei Z, Zhou Y, Pei H.
europepmc   +1 more source

Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Recently, zolbetuximab combined with chemotherapy has been approved as a first‐line treatment for advanced gastric cancer (GC). However, to date, no endoscopic images demonstrating endoscopic complete response (eCR) to zolbetuximab plus chemotherapy have been reported.
Akinori Sasaki, Tomohiro Yamaba, Ayu Tachibana, Rika Kimura, Gaku Uchiyama, Tsubasa Yoshioka, Risa Okamoto   +6 more
wiley   +1 more source

Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study. [PDF]

J Pers Med
Ozkerim U, Isik D, Kinikoglu O, Oksuz S, Altintas YE, Akdag G, Yildirim S, Basoglu T, Surmeli H, Odabas H, Turan N.   +10 more
europepmc   +1 more source

Treatment and survival of patients with esophageal and gastric cancer in the Netherlands and Belgium: A population‐based comparison

International Journal of Cancer, Volume 158, Issue 7, Page 1868-1880, 1 April 2026.
What's new? Marked differences in esophageal and gastric cancer survival rates exist between the Netherlands and Belgium, for reasons that remain unclear. In this study, the authors in‐vestigated these differences and attempted to identify contributing factors.
Benthe H. Doeve, Steven C. Kuijper, Geert Silversmit, Lien van Walle, Philippe Nafteux, Camiel Rosman, Pauline A. J. Vissers, Paul Jeene, Laurens V. Beerepoot, Sarah Derks, Amine Karimi, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, Rob H. A. Verhoeven   +13 more
wiley   +1 more source

Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites. [PDF]

World J Gastrointest Oncol
Matsumoto T, Sugimoto S, Omori R, Makiyama C, Nakasya A, Nagai H, Yasui H, Higashi R, Sasamoto A, Satake H.   +9 more
europepmc   +1 more source

Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review

International Journal of Dermatology, EarlyView.
Niyoosha Yoosefi, Adrian Tabari, Jeffrey Donovan   +2 more
wiley   +1 more source

Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT

International Journal of Cancer, Volume 158, Issue 6, Page 1690-1702, 15 March 2026.
What's new? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald, Lothar Müller, Eyck von der Heyde, Uwe M. Martens, Carolin Lennartz, Michaela Koska, Karin Potthoff, Anja Kaiser‐Osterhues, Carsten Grüllich, Michael Staehler, Martina Jänicke, Dominik Marschner, the CARAT Registry Group   +15 more
wiley   +1 more source

Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER. [PDF]

PLoS One
Gao Y, Jiang S, Cui Y, Wang Y, Yu L.
europepmc   +1 more source

Impact of melanoma histological regression on first‐line immunotherapy response in stage‐IV disease

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jean‐Baptiste Such, Sandrine Mansard, Mélissa Zlobecki, Carole Chevenet, Céline Lambert, Marie Bachelerie, Jacques Rouanet   +6 more
wiley   +1 more source